StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) shareholders

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.60−0.07 (-4.19%)

Close on Nov 17, 2026Market cap $79.75MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
4.4%
2M of 50M shares
Institutional holders
13
4 new, 5 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $368.00K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Alex Keun Mo Yang
Joint filing with Mstone Partners Healthcare Limited (47.40%)
22,744,79648.00%13D (active)Jan 29, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PLYXValueChange% of portfolio
Vanguard Capital Management LLC1,657,8723.33%$4.41M−5160.00%
Geode Capital Management, LLC170,9980.34%$455.08K+3250.00%
Vanguard Fiduciary Trust Co105,0720.21%$279.49K+5160.00%
Hrt Financial LP82,0940.16%$218.00KNew0.00%
State Street Corp58,1040.12%$154.56K–0.00%
BlackRock, Inc.41,0120.08%$109.09K–0.00%
Jane Street Group, LLC31,4410.06%$83.63KNew0.00%
Northern Trust Corp27,9870.06%$74.45K–0.00%
Allworth Financial LP7,7270.02%$20.55KNew0.00%
Vanguard Global Advisers, LLC6,3180.01%$16.81K–0.00%
Tower Research Capital LLC (TRC)3,0020.01%$7.99K+1,2210.00%
UBS Group AG1,2830.00%$3.41K−12,1960.00%
Fortitude Family Office, LLC1890.00%$503New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026132M4.4%4 / 32 / 50M0M
Q1 2026142M4.5%14 / 00 / 02M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of PLYXValue% of fundAs of
Vanguard Total Stock Market Index Fund1,468,0142.95%$3.90M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund142,0330.28%$377.81K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund67,0790.13%$219.35K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund28,6480.06%$93.68K0.00%May 31, 2026
Fidelity Total Market Index Fund26,4500.05%$86.49K0.00%May 31, 2026
Vanguard Balanced Index Fund25,9690.05%$69.08K0.00%Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund21,8560.04%$58.14K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund19,6050.04%$64.11K0.00%May 31, 2026
Total Stock Market Index Trust8650.00%$2.30K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Alex Keun Mo YangChief Executive Officer, Director, 10% owner––May 28, 2026
G. Michael LandisChief Financial Officer, Director228,2250.46%Feb 20, 2026
Lisa BollingerChief Medical Officer150,3580.30%Jan 29, 2026
Andrew John OChief Investment Officer471,8080.95%Jan 29, 2026
Partners Healthcare Ltd MstoneDirector, 10% owner25,633,24951.42%May 28, 2026
III Francis A. BraunDirector––Jan 29, 2026
Mitchel BergerDirector––Jan 29, 2026
Charles S. RyanDirector––Jan 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Partners Healthcare Ltd Mstone
Director, 10% owner
May 27, 2026Buy+88,453$4.07$360.00K24,233,249
G. Michael Landis
Chief Financial Officer, Director
Feb 18, 2026Buy+2,867$2.79$8.00K228,225

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.59%
0M shares short
Days to cover
6.5
At 0M shares a day
Change since last report
+16.9%
From 0M shares
Short volume, 20 days
53.2%
Of volume reported to FINRA

Shares sold short, last 9 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Polaryx Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,911 shares on Aug 27, 2026 over the last 90 days.

See a number that looks wrong?